0000899243-20-021325.txt : 20200804
0000899243-20-021325.hdr.sgml : 20200804
20200804212704
ACCESSION NUMBER: 0000899243-20-021325
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200801
FILED AS OF DATE: 20200804
DATE AS OF CHANGE: 20200804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fink Eric
CENTRAL INDEX KEY: 0001784038
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 201075390
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001784038
Fink Eric
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Human Resources Officer
Common Stock
2020-07-31
5
A
0
E
263
55.47
A
263
D
Common Stock
2020-08-01
4
M
0
3020
A
3283
D
Common Stock
2020-08-01
4
F
0
829
67.48
D
2454
D
Restricted Stock Units
2020-08-01
4
M
0
3020
0.00
D
Common Stock
3020
21140
D
Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(b) and Rule 16b-3(c).
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,020 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/ Tricia Suvari, as Attorney-in-Fact
2020-08-04